Buying replicel stock thread

[ccmethinning]

One other catalyst I saw. It looks like there are a bunch of the "penny stock companies" and "momentum" stock investing services that are published reports on Replicel in the last couple of days in addition to NBT. Here are a couple for example:

http://www.trade4all.com/view_newsle...+-+REPCF&desc=...

http://stockreads.com/Stock-Newsletter.aspx?id=58687&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+StockNewsletters+%28Stock+Newsletters%29

If just a few people that are into penny stock investing start buying stock, that can be another explanation for today's activity.

Man, RepliCel paying for all these stock ads is quite unsettling. I could tolerate NBT, although Tobin Smith is a hack, he at least has some credibility. These though seem like the kind of scam stock e-mails that end up in my spam folder. If their procedure is gonna work, why pay some penny stock blogs to pump your stock just 2 weeks before the "big reveal"? If it works, it will be on the front page of Yahoo finance in an article written by an objective journalist and every retail investor in the world will know about it.

[gmonasco]

If their procedure is gonna work, why pay some penny stock blogs to pump your stock just 2 weeks before the "big reveal"?

Because it likely isn't going to be a "big reveal"; it's just going to be a determination of whether there's enough potential to merit continuing with more Phase II trials, where plenty of other treatments have crashed and burned.

[ccmethinning]

Because it likely isn't going to be a "big reveal"; it's just going to be a determination of whether there's enough potential to merit continuing with more Phase II trials, where plenty of other treatments have crashed and burned.

NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.

http://www.cloudinvestor.com/report/bloomberg-says-it-best-the-big-business-of-hair-loss

http://cloudinvestor.com/report/all-19-subjects-in-replicels-clinical-trial-complete-first-phase

[yeahyeahyeah]

NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.

http://www.cloudinvestor.com/report/bloomberg-says-it-best-the-big-business-of-hair-loss

http://cloudinvestor.com/report/all-...te-first-phase

I think they are onto something tbh.

Imagine HOW EMBARRASSING it would be if it turns out to be bullshit?

Think about it.

[gmonasco]

NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.

Something that's a "big reveal" to stock pumpers/speculators isn't necessarily so to the mainstream news media.

We've all seen how news stories about "cures for baldness" come and go: they hit the news cycle for a day or so, and then they disappear. Without some dramatic visual evidence to show off (like B/A pictures of a NW6 turned NW2), I don't see Replicel's results getting much more play than any of those other stories, no matter how the trials turn out -- no dramatic visual evidence is going to come out of injecting the temples of a handful of test subjects.

[gmonasco]

Imagine HOW EMBARRASSING it would be if it turns out to be bullshit?

Probably not so much. Other than guys on Internet hair loss forums, some stock speculators, and those involved in a very specialized area of the medical industry, hardly anyone is paying much attention to Replicel right now.

[lpenergy]

I just heard from Heather at Replicel. Here is what she said:


"Good Afternoon Mr. (named removed),

The deadline to file the 2011 Annual Report is April 29th. The Company is on track to file on or before that date.



Kind Regards,



Heather"


My theory is that the trial results will be contained in the Annual report. As most companies do not release or file over the weekend, that could put it back to April 27th. Additionally, from an information sensitivity standpoint, it may make sense to have it released prior to having it included in the auditor-reviewed annual report, as the chance of a leak would be decreased. That is purely a guess on my part, however.

[gmonasco]

Replicel stock is down quite a bit today (from $2.15 to $1.80) on considerable volume.

[NotBelievingIt]

Replicel stock is down quite a bit today (from $2.15 to $1.80) on considerable volume.

..and you posted too early, it only lost about 1% at the end of the day

So its actually a tremendously good sign that there are buyers waiting to scoop it up under $2.

[gmonasco]

The volume has been comparatively huge the last few days, but the closing price of the stock has hardly changed at all.

[ccmethinning]

Mixed day for RepliCel today. BIG opening volume with a relatively stable price. Then a drop on big volume and a rebound on moderate volume. There was more volume on the downward moves than there was on the upward ones.

[uninformed]

Stop analysizing stock movements and volumes they indicate nothing but speculations and/or opportunists trying to grab some quick bucks....

at this point of time anyway

[lpenergy]

What I see is a whole lot of churning going on. Current owners of shares are selling and new buyers are coming in. That is why we have higher volume, yet the shares are not going anywhere.

So far, Replicel has paid the following companies to push info on their stock:

Blue Wave Advisors 45,000
TooNiceStocks 33,000

Link:

http://stockpromoters.com/News-Letters.aspx?symbol=REPCF

This in addition to NBT. I am not an expert on penny stocks, don't normally invest in them. I have made an exception on this one. I don't know, maybe this is something that an unknown company needs to do so that they don't end up announcing their discovery to the wind and realize that the only people who know about it are a few chat room members.

Taking a glass is half full view, if there is greater visibility out there for Replicel, maybe some people don't necessarily buy the stock immediately, but have it on their watch list, and if results are good, and the stock takes off a bit, there could be additional buyers of the stock.

[gmonasco]

TapImmune (OTC: TPIV), RepliCel Life Sciences (OTC: REPCF) and American Fiber Green Products (AFBG) are three small cap stocks (the first two being biotech stocks and the last being an eco-friendly green stock) that have recently been the subject of promotions and hence, could use a reality check. After all, paid promotions can work both ways as they send a stock upward thanks to mentions in investment newsletters and investor alerts but then gravity forces the stock back down to earth unless the companies promoted are actually viable. So can small cap stocks TapImmune (TPIV), RepliCel Life Sciences (REPCF) and American Fiber Green Products (AFBG) move beyond paid promotions and stand on their own feet or should investors just give all three a pass? Here is a reality check to help you decide:

RepliCel Life Sciences is developing a scientific technology that has the potential to become the world's first, minimally invasive, permanent solution for hair loss in men and women. According to various disclosures, various $33k, $40k and $45k transactions have been paid to promote RepliCel Life Sciences. However and on Monday, RepliCel Life Sciences only rose 0.49% to $2.06 (REPCF has a 52 week trading range of $1.60 to $3.50 a share) for a market cap of $88.89 million but the stock is down 12.3% since the start of the year as well as over the past year. Hence and so far, the promotions appear to not be helping RepliCel Life Sciences just yet while the stock also has just announced the closing of a private placement where it issued 430,033 units at a price of $1.50 per unit for gross proceeds of $645,050. Investors should be aware that RepliCel Life Sciences has reported no revenues; net losses C$2.54M (2010), C$0.56M (2009) and C$0.02M (2008) for the past three years and net losses of C$0.89M (most recent reporting quarter), C$1.81M and C$0.71M for the first three quarters of 2011; and had C$1.21M in cash and short-term investments to cover C$0.27M in current liabilities at the end of last September. Nevertheless and if RepliCel Life Sciences does find or have a cure or permanent solution for hair loss, the stock won’t need any promotions as it will surge on its own merits.

http://www.smallcapnetwork.com/Promoted-Small-Cap-Biotech-or-Green-Stocks-Needing-a-Reality-Check-TapImmune-TPIV-RepliCel-Life-Sciences-REPCF-American-Fiber-Green-Products-AFBG/s/via/3414/article/view/p/mid/1/id/647/

[PvH]

i pray all these hair loss experts on TBT takes matter into their own hands to come up with a solution instead of just digging and digging and digging then trashing each other with dirt.